Outset Medical, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Outset Medical reported Q2 2026 revenue of $31.6M (flat YoY, +14% sequentially) with gross margin expanding 420bps to 42%. The company signed a three-year, $40M agreement with HCA Healthcare to refresh Tablo systems across the nation's largest health system—the first refresh agreement marking a new revenue stream. Cash position remains solid at $151M; company maintained 2026 guidance of $125–$130M revenue (+5–9% growth).
Why this rating
HCA deal ($40M over 3 years ≈ $13.3M/yr annualized) is 10.7% of 2026 guidance midpoint—material new revenue stream signaling market validation and repeat buying. However, core Q2 revenue flat YoY despite margin gains, and company still burning cash ($9.5M/quarter); profitability still distant. Meaningful but not transformational relative to company scale.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.